CL2021000622A1 - Uso de niclosamida para la preparación de un medicamento para el tratamiento de colitis autoinmune, una enfermedad inflamatoria intestinal, colitis autoinmune iatrogénica, divisional de la solicitud de patente nº 559-2018. - Google Patents

Uso de niclosamida para la preparación de un medicamento para el tratamiento de colitis autoinmune, una enfermedad inflamatoria intestinal, colitis autoinmune iatrogénica, divisional de la solicitud de patente nº 559-2018.

Info

Publication number
CL2021000622A1
CL2021000622A1 CL2021000622A CL2021000622A CL2021000622A1 CL 2021000622 A1 CL2021000622 A1 CL 2021000622A1 CL 2021000622 A CL2021000622 A CL 2021000622A CL 2021000622 A CL2021000622 A CL 2021000622A CL 2021000622 A1 CL2021000622 A1 CL 2021000622A1
Authority
CL
Chile
Prior art keywords
autoimmune colitis
niclosamide
preparation
treatment
inflammatory bowel
Prior art date
Application number
CL2021000622A
Other languages
English (en)
Spanish (es)
Inventor
Gary D Glick
Luigi Franchi
Original Assignee
First Wave Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by First Wave Bio Inc filed Critical First Wave Bio Inc
Publication of CL2021000622A1 publication Critical patent/CL2021000622A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
CL2021000622A 2015-09-01 2021-03-15 Uso de niclosamida para la preparación de un medicamento para el tratamiento de colitis autoinmune, una enfermedad inflamatoria intestinal, colitis autoinmune iatrogénica, divisional de la solicitud de patente nº 559-2018. CL2021000622A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562213016P 2015-09-01 2015-09-01
US201562241508P 2015-10-14 2015-10-14

Publications (1)

Publication Number Publication Date
CL2021000622A1 true CL2021000622A1 (es) 2021-10-01

Family

ID=58097295

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000622A CL2021000622A1 (es) 2015-09-01 2021-03-15 Uso de niclosamida para la preparación de un medicamento para el tratamiento de colitis autoinmune, una enfermedad inflamatoria intestinal, colitis autoinmune iatrogénica, divisional de la solicitud de patente nº 559-2018.

Country Status (21)

Country Link
US (11) US10292951B2 (enExample)
EP (1) EP3344274A4 (enExample)
JP (2) JP6955648B2 (enExample)
KR (1) KR20180080189A (enExample)
CN (1) CN109562137A (enExample)
AU (2) AU2016315852B2 (enExample)
BR (1) BR112018004069A2 (enExample)
CA (1) CA2997136A1 (enExample)
CL (1) CL2021000622A1 (enExample)
CO (1) CO2018003465A2 (enExample)
CR (1) CR20180185A (enExample)
EA (1) EA201890618A1 (enExample)
HK (1) HK1258048A1 (enExample)
IL (1) IL257801A (enExample)
MX (3) MX2018002586A (enExample)
PE (1) PE20181295A1 (enExample)
PH (1) PH12018500448A1 (enExample)
SG (1) SG10201914118SA (enExample)
TN (1) TN2018000069A1 (enExample)
UA (1) UA125747C2 (enExample)
WO (1) WO2017040864A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11452692B2 (en) 2018-09-28 2022-09-27 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarinic receptor activation

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006244068B9 (en) 2005-05-10 2012-10-25 Incyte Holdings Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
SG192485A1 (en) 2008-07-08 2013-08-30 Incyte Corp 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
PL3061821T3 (pl) 2009-07-22 2020-01-31 PureTech Health LLC Kompozycje do leczenia zaburzeń łagodzonych przez aktywację receptora muskarynowego
EP3967312A1 (en) 2014-09-12 2022-03-16 UNION therapeutics A/S Antibacterial use of halogenated salicylanilides
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
CN104880428B (zh) * 2015-06-23 2016-07-06 山西振东安特生物制药有限公司 一种胶体果胶铋或含胶体果胶铋制剂中铋含量的测定方法
EA201890618A1 (ru) 2015-09-01 2018-10-31 Ферст Вэйв Байо, Инк. Способы и композиции для лечения состояний, ассоциированных с аномальными воспалительными ответами
AU2016349501B2 (en) * 2015-11-04 2022-07-21 Incyte Corporation Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor
GB201604484D0 (en) 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
US11278551B2 (en) 2017-03-15 2022-03-22 Georgetown University Treating cancer with a CCK receptor inhibitor and an immune checkpoint inhibitor
CA3057284A1 (en) 2017-03-21 2018-09-27 Novalead Pharma Inc. Therapeutic agent for phosphodiesterase inhibition and its related disorders
SG11201909955XA (en) 2017-05-02 2019-11-28 Merck Sharp & Dohme Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
KR102459936B1 (ko) * 2017-10-13 2022-10-27 주식회사 엘지생활건강 알칸닌을 포함하는 구강질환 예방 또는 치료용 조성물
WO2019126739A1 (en) 2017-12-21 2019-06-27 Shepherd Therapeutics, Inc. Pyrvinium pamoate anti-cancer therapies
AU2019242628A1 (en) 2018-03-26 2020-09-24 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
MD3817751T2 (ro) * 2018-07-03 2025-10-31 Fennec Pharmaceuticals Inc Compoziții de tiosulfat de sodiu anhidru
IL261670B (en) * 2018-09-06 2019-06-30 Tudu Holdings Ltd A preparation that includes magnesium and its uses
CN109180600A (zh) * 2018-09-21 2019-01-11 五邑大学 一种麝香草酚类似物及其应用
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3639822A1 (en) * 2018-10-15 2020-04-22 Universität Regensburg Compound for use in the treatment of a disease characterized by dysregulated mucus production and/or secretion
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN120842406A (zh) * 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
EP3876990A4 (en) 2018-11-07 2023-09-06 Merck Sharp & Dohme LLC CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
WO2020198051A1 (en) * 2019-03-22 2020-10-01 Mannkind Corporation Inhalable dry powders
JP7730548B2 (ja) * 2019-04-18 2025-08-28 プリヴェップ インコーポレイテッド 治療用組合せ、液状の薬学的組成物、それらの調製のためのキット、およびこれらの使用方法
CN111032030B (zh) * 2019-04-28 2023-02-17 深圳市中医院 氯硝柳胺乙醇胺盐在制备治疗系统性红斑狼疮及其并发症的药物中的应用
CN112007036B (zh) * 2019-05-29 2022-01-21 百岳特生物科技（上海）有限公司 化合物及其组合物用于制备缓解肺上皮细胞发炎的医药品的用途
CN110200935B (zh) * 2019-06-03 2021-03-02 浙江得恩德制药股份有限公司 一种胶体果胶铋胶囊及其制备工艺
WO2021005676A1 (ja) * 2019-07-08 2021-01-14 株式会社Moresco マイクロエマルションを調製するための組成物、マイクロエマルション、これらの製造方法、及びマイクロエマルションの利用
CN112341397B (zh) * 2019-08-09 2023-05-23 成都苑东生物制药股份有限公司 吡嗪类衍生物或盐、异构体、其制备方法及用途
EP3797771B1 (en) * 2019-09-03 2022-02-23 Square Power Ltd Rebamipide for use in prophylaxis and treatment of celiac disease
US20210114973A1 (en) * 2019-10-18 2021-04-22 First Wave Bio, Inc. Pharmaceutical formulations
KR102300846B1 (ko) * 2019-11-01 2021-09-09 서울대학교산학협력단 면역 활성 개선용 조성물 및 이의 방법
CN111122523B (zh) * 2019-12-06 2021-09-28 山西大学 一种快速识别Ag+和Cys的三相输出功能的分子逻辑门及其构建方法
WO2021142238A1 (en) 2020-01-10 2021-07-15 First Wave Bio, Inc. Deuterated niclosamide
WO2021142240A1 (en) 2020-01-10 2021-07-15 First Wave Bio, Inc. Compositions comprising niclosamide for use in treating conditions associated with an abnormal inflammatory response
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
TW202200121A (zh) 2020-03-16 2022-01-01 美商費斯特威弗生技股份有限公司 治療方法
BR112022018615A2 (pt) * 2020-03-19 2022-12-20 Trizell Ltd Sistema de armazenamento de vírus sensível à temperatura
US12076315B2 (en) 2020-03-20 2024-09-03 Clear Creek Bio, Inc. Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
CN112914547A (zh) * 2020-03-22 2021-06-08 复旦大学附属华山医院 内源性神经干细胞磁共振无创性示踪技术体系及建立方法
MX2022012359A (es) * 2020-04-01 2022-10-21 Union Therapeutics As Formulacion.
US11045434B1 (en) * 2020-04-01 2021-06-29 UNION therapeutics A/S Niclosamide formulations for treating disease
US20210346324A1 (en) * 2020-05-05 2021-11-11 NeuroBo Therapeutics, Inc. Niclosamide Formulations and Methods of Use
CA3183146A1 (en) * 2020-05-13 2021-11-18 The Regents Of The University Of California Thiol-containing compounds for use in treating coronavirus
CN112057623A (zh) * 2020-06-03 2020-12-11 江苏靶标生物医药研究所有限公司 一种磷脂酰丝氨酸在制备治疗炎症性肠病药物中的应用
WO2021255218A1 (en) * 2020-06-19 2021-12-23 Charité - Universitätsmedizin Berlin A pharmaceutical combination comprising an anti-viral protonophore and a serine protease inhibitor
CN111650307A (zh) * 2020-07-13 2020-09-11 重庆医药高等专科学校 一种同时对酒中解热镇痛类药品非法添加物定性定量检测的方法及应用
CN116322669A (zh) * 2020-07-23 2023-06-23 普渡研究基金会 治疗sars-cov-2、其它病毒性疾病和癌症的ohpp配制的氯硝柳胺
WO2022036309A2 (en) * 2020-08-14 2022-02-17 Mayo Foundation For Medical Education And Research Methods and materials for tissue ablation
WO2022046668A1 (en) * 2020-08-22 2022-03-03 Luc Montagnier Compositions and methods for reducing the transmissivity of illnesses
CN111920824A (zh) * 2020-09-11 2020-11-13 余朝权 一种治疗伤口的中药组合物
KR102636847B1 (ko) 2020-09-18 2024-02-19 경북대학교 산학협력단 티아민 유도체를 포함하는 이식편대숙주질환 예방 또는 치료용 약학적 조성물
CN114246852B (zh) * 2020-09-21 2024-08-16 暨南大学 一种药物组合物在心脑血管疾病中的应用
KR102378590B1 (ko) * 2020-09-28 2022-03-24 (주)위바이오트리 난용성 약물을 포함하는 금속 (수)산화물 복합체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
WO2022093871A1 (en) * 2020-10-26 2022-05-05 The Regents Of The University Of California Sars-c0v-2 inactivation by ethacridine
CN112342028B (zh) * 2020-10-28 2021-07-09 中铁建华南建设(广州)高科技产业有限公司 盾构分散剂及其制备方法和应用
KR20220059436A (ko) * 2020-11-02 2022-05-10 (주)아이엠디팜 신규한 공결정, 이를 포함하는 약학 조성물 및 이의 제조 방법
CN112526032B (zh) * 2020-12-28 2022-05-17 北京金城泰尔制药有限公司 聚甲酚磺醛的检测方法
WO2022147499A1 (en) * 2021-01-04 2022-07-07 Neurobo Pharmaceuticals, Inc. Method of treating viral infections with a combination of niclosamide and gemcabene
WO2022159326A1 (en) 2021-01-19 2022-07-28 Erimos Pharmaceuticals, Llc Terameprocol and nordihydroguaiaretic acid (ndga) derivatives as coronavirus anti-viral agents
WO2022162604A1 (ko) * 2021-01-28 2022-08-04 (주)아이엠디팜 카모스타트 및 니클로사마이드를 포함하는 공결정, 이를 포함하는 약학 조성물 및 이의 제조 방법
CN112826795B (zh) * 2021-03-23 2022-08-30 重庆医科大学 一种载汉防己甲素脂质体制剂及其制备方法和应用
US20220304959A1 (en) * 2021-03-26 2022-09-29 First Wave Biopharma Treatment of long haulers syndrome with niclosamide
CN113368064B (zh) * 2021-06-08 2022-06-28 吉林津升制药有限公司 一种烟酸冻干粉及其制备方法
CN114134195B (zh) * 2021-11-03 2024-06-11 南方科技大学 预防前列腺癌的药剂的筛选方法、硝唑尼特在制药中的应用
WO2023096896A2 (en) * 2021-11-23 2023-06-01 nference, inc. Detection of covid-19 associated cardiac injury and vaccine-associated myocarditis
CN113908154A (zh) * 2021-11-29 2022-01-11 中国药科大学 硝唑尼特及其体内代谢物替唑尼特在抗银屑病及银屑病样皮肤炎症中的应用
CN114393662A (zh) * 2021-12-21 2022-04-26 凭祥青山中密度纤维板有限公司 一种环保中密度纤维板的制备方法
JP2025518339A (ja) * 2022-01-31 2025-06-12 リビオネックス・インコーポレイテッド 鉄キレート化のための新規液体製剤
WO2023168022A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocybin
CN114796135B (zh) * 2022-03-29 2023-04-07 海南久常制药有限公司 一种硫糖铝口服制剂及其制备方法
CN114652734A (zh) * 2022-03-31 2022-06-24 李红梦 一种祛痘的药物组合物及其制备方法
CN114767871B (zh) * 2022-04-19 2023-04-07 中国工程物理研究院机械制造工艺研究所 介孔硅载药体系及制备方法和介孔硅载药
CN117045657A (zh) * 2022-05-12 2023-11-14 广州嘉越医药科技有限公司 一种药物组合及其应用
WO2024029639A1 (ko) * 2022-08-02 2024-02-08 제이투에이치바이오텍 주식회사 3성분 프로드럭, 이의 약학적 조성물 및 의약 용도
CN115494231A (zh) * 2022-09-02 2022-12-20 武汉三鹰生物技术有限公司 一种蛋白酶抑制剂混合物及其制备方法与应用
CN115739028B (zh) * 2022-11-26 2024-04-02 西南政法大学 一种精神活性物质吸附剂及其应用
CN116036289B (zh) * 2023-02-03 2025-05-06 中国药科大学 一种增强铁死亡治疗效果的纳米制剂及其制备方法和应用
CN116077424B (zh) * 2023-02-17 2025-06-03 重庆大学 一种多功能仿生水凝胶及其制备方法和应用
US20240299361A1 (en) * 2023-02-28 2024-09-12 Verté Therapeutics, Llc Veterinary transdermal gel comprising ondansetron, and related methods
CN116139116A (zh) * 2023-03-30 2023-05-23 中南大学湘雅医院 氯硝柳胺在抑制急性肝衰竭中的应用
CN116531366B (zh) * 2023-05-23 2025-02-14 新乡医学院 罗替戈汀的药物新用途
WO2025037323A1 (en) * 2023-08-12 2025-02-20 Pavan Kumar Kothapuvari Pharmaceutical compositions for treatment of dry eye disease and associated disorders
CN117899225A (zh) * 2024-01-19 2024-04-19 芮城绿曼生物药业有限公司 一种增强免疫力的兽用抗菌注射剂、制备方法及应用
WO2025216847A1 (en) * 2024-04-12 2025-10-16 Advancion Corporation Formulations comprising 3-amino-2-butanol and use thereof in electrical and electronic applications
CN119055625B (zh) * 2024-07-23 2025-09-09 湖北工业大学 Tiratricol在制备抗ADV7病毒药物中的应用
CN120204184A (zh) * 2025-02-17 2025-06-27 深圳市第三人民医院(深圳市肝病研究所) 阿米替林和/或其衍生物的应用、结核分枝杆菌抑制剂和药物组合物
CN119700664B (zh) * 2025-02-28 2025-06-20 山东新时代药业有限公司 含有活性成分琥珀酸普芦卡必利的注射液及其制备方法
CN120713881B (zh) * 2025-08-21 2025-12-05 南方科技大学 氯硝柳胺在治疗器官移植排斥反应中的应用

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3079297A (en) 1960-05-31 1963-02-26 Bayer Ag Method of combating gastropods
US3927195A (en) * 1974-01-31 1975-12-16 Lilly Industries Ltd Production of capsules
FR2505798B1 (fr) 1981-05-14 1986-07-25 Pari Symac Perfectionnement aux dispositifs comportant un ressort helicoidal utilise comme organe de transfert, d'extraction, de dosage ou de melange
NZ223200A (en) 1988-01-15 1989-01-06 Ancare Distributors Anthelmintic compositions containing 2',5-dicloro-4'-nitrosalicylanilide and non aqueous carrier
DE4005528C2 (de) 1990-02-22 1998-01-15 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
US5280784A (en) 1990-09-19 1994-01-25 Paul Ritzau Pari-Werk Gmbh Device in particular and inhalating device for treating the lung and the respiratory tracts
DE59107894D1 (de) 1991-03-21 1996-07-11 Ritzau Pari Werk Gmbh Paul Vernebler insbesondere zur Anwendung in Geräten für die Inhalationstherapie
DK0540774T3 (da) 1991-11-07 1995-07-10 Ritzau Pari Werk Gmbh Paul Væskeforstøver
ATE155695T1 (de) 1991-11-07 1997-08-15 Ritzau Pari Werk Gmbh Paul Vernebler insbesondere zur anwendung in geräten für die inhalationstherapie
DE4225928A1 (de) 1992-08-05 1994-02-10 Ritzau Pari Werk Gmbh Paul Zerstäubervorrichtung mit Heizeinrichtung
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
DE4310575C1 (de) 1993-03-31 1994-09-15 Ritzau Pari Werk Gmbh Paul Vorrichtung zum Erzeugen von Aerosolpulsen
ATE168289T1 (de) 1993-12-17 1998-08-15 Pari Gmbh Zerstäuberdüse
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US6000394A (en) 1994-10-26 1999-12-14 Paul Rizau Pari-Werk Gmbh Generation of an aerosol of an exact dose
US5663155A (en) * 1994-11-30 1997-09-02 The University Hospital Compositions for the treatment of parasitic infections
DE19520622C2 (de) 1995-06-06 2003-05-15 Pari Gmbh Vorrichtung zum Vernebeln von Fluiden
DE19602628C2 (de) 1996-01-25 2000-06-29 Pari Gmbh Vernebler
EP0821970A1 (en) 1996-08-02 1998-02-04 Edward Henri Charles Verhaeren Carrier composition for influencing the tight junction permeability
US6503881B2 (en) 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
DE19734022C2 (de) 1997-08-06 2000-06-21 Pari Gmbh Inhalationstherapiegerät mit einem Ventil zur Begrenzung des Inspirationsflusses
US5905090A (en) 1998-04-29 1999-05-18 Italfarmaco S.P.A. Analogues of the active metabolite of leflunomide
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
DE19827228C2 (de) 1998-06-18 2000-07-13 Pari Gmbh Flüssigkeitszerstäubervorrichtung
DK1098641T3 (en) 1998-07-27 2016-08-15 St Jude Pharmaceuticals Inc Chemically induced intracellular hyperthermia
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
DE19962110C2 (de) 1999-12-22 2003-06-12 Pari Gmbh Inhalationsvernebler mit einstückigem Ventilelement
WO2001089523A1 (en) * 2000-05-26 2001-11-29 Novo Nordisk A/S New pharmaceutical composition and the process for its preparation
UA82827C2 (en) 2000-12-18 2008-05-26 Inhibitors against the production and release of inflammatory cytokines
WO2002051397A1 (en) 2000-12-22 2002-07-04 Ishihara Sangyo Kaisha, Ltd. Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
CA2436418A1 (en) 2001-01-30 2002-08-08 Board Of Regents, The University Of Texas Systems Process for production of nanoparticles and microparticles by spray freezing into liquid
US20040022861A1 (en) 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
US20040071757A1 (en) 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
WO2004006906A2 (en) 2002-07-15 2004-01-22 Combinatorx, Incorporated Methods for the treatment of neoplasms
US9175906B2 (en) 2003-01-15 2015-11-03 Board Of Regents, The University Of Texas System Drug particles from freezing onto a surface
US7544712B1 (en) 2003-05-28 2009-06-09 National Health Research Insitutes Treatment of coronavirus infection
WO2005001052A2 (en) 2003-06-06 2005-01-06 University Of Massachusetts Modulation of apoptosis
US7249224B2 (en) 2003-08-05 2007-07-24 Newisys, Inc. Methods and apparatus for providing early responses from a remote data cache
DE10340277B4 (de) 2003-08-29 2006-11-23 Bio-Gate Bioinnovative Materials Gmbh Körperpflegemittel mit Silber-Agglomeraten
EP1774028A4 (en) 2004-07-07 2008-05-07 Dana Farber Cancer Inst Inc METHOD AND COMPOSITIONS FOR TREATING OBESITY
CN1626506A (zh) 2004-08-10 2005-06-15 李志良 高纯度、高收率氯硝柳胺的制备
US9061027B2 (en) 2004-08-27 2015-06-23 Board Of Regents, The University Of Texas System Enhanced delivery of drug compositions to treat life threatening infections
US20100041657A1 (en) 2005-05-11 2010-02-18 Novo Nordick A/S Haloalkylsulfone substituted compounds useful for treating obesity and diabetes
US20090062396A1 (en) 2005-05-23 2009-03-05 Novo Nordisk A/S Novel Haloalkoxy-Substituted Salicylic Anilides
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
EP2049137A4 (en) 2006-08-08 2013-05-01 Univ California SALICYLANILIDES AS AMPLIFIERS OF THE ORAL RELEASE OF THERAPEUTIC PEPTIDES
CA3027598C (en) 2007-01-10 2020-07-21 Board Of Regents The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
DK2170283T3 (en) 2007-06-22 2019-04-15 Univ Texas CREATION OF STABLE SUBMICRON Peptide OR PROTEIN PARTICLES BY THIN FILM FREEZING
US8262657B2 (en) 2007-08-16 2012-09-11 Nutek Orthopaedics, Inc. External fixation apparatus with adjustable pin clamping means and convergent bone pins
CN101877971A (zh) 2008-01-10 2010-11-03 赢创罗姆有限公司 具有活性物质在结肠中增强的释放的包衣药物或营养制剂
DK2252275T3 (en) 2008-02-13 2018-03-05 Univ Texas CREATED NON-OPEN FLOCKS OF ANISOTROPIC PARTICLES FOR IMPROVED TRANSPORT INTO THE Lungs
EP2123626A1 (en) 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
AU2009307753A1 (en) 2008-10-22 2010-04-29 Metaproteomics, Llc Novel mitochondrial uncoupling methods and compositions for enhancing adipocyte thermogenesis
CU23701A1 (es) 2008-12-29 2011-09-21 Ct Ingenieria Genetica Biotech Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i
EA030679B1 (ru) 2009-06-26 2018-09-28 РОМАРК ЛЭБОРЕТЕРИЗ Эл.Си. Соединения и способы лечения гриппа
CN101601670B (zh) 2009-06-30 2014-06-04 青岛蔚蓝生物股份有限公司 一种宠物用复方氯硝柳胺驱虫片剂及其制备方法
KR100990110B1 (ko) 2009-08-18 2010-10-29 엘지전자 주식회사 태양 전지
WO2011035321A1 (en) 2009-09-21 2011-03-24 Duke University Treatment of wnt/frizzled-related diseases
US9206394B2 (en) 2010-02-03 2015-12-08 The University Of Tokyo Method for reconstructing immune function using pluripotent stem cells
GB201015079D0 (en) 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US20130231312A1 (en) 2010-11-16 2013-09-05 Shengkan Jin Treatment of type ii diabetes and diabetes-associated diseases with safe chemical mitochondrial uncouplers
EP2699319B1 (en) 2011-04-18 2017-08-09 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Niclosamide for the treatment of cancer metastasis
US9572820B2 (en) 2011-05-10 2017-02-21 Stc.Unm Methods of treating autophagy-associated disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits
EP2731605A4 (en) * 2011-07-15 2015-02-25 Sla Pharma Ag PHARMACEUTICAL COMPOSITIONS FOR RECTAL ADMINISTRATION
WO2013169939A2 (en) 2012-05-08 2013-11-14 Aeromics, Llc New methods
WO2014023329A1 (en) 2012-08-06 2014-02-13 Life And Brain Gmbh Niclosamide and its derivatives for use in the treatment of solid tumors
CN102861014A (zh) * 2012-10-16 2013-01-09 天津必佳药业集团有限公司 一种畜禽用抗蠕虫病复方氯硝柳胺片及其制备方法
CN103891720B (zh) * 2012-12-27 2016-02-17 陕西汤普森生物科技有限公司 一种含有螺枯威的复配杀螺组合物
CA3159085A1 (en) 2013-01-14 2014-07-17 Clinics Operations Limited Combination cancer therapeutics and uses thereof
US9138425B2 (en) * 2013-03-12 2015-09-22 Patheon Inc. Drug delivery system to increase bioavailability
HUE042996T2 (hu) 2013-04-23 2019-07-29 Zx Pharma Llc Bélben oldódó bevonatú, fehérjetartalmú alapbevonattal ellátott, több részecskét tartalmazó készítmény
US9669036B2 (en) 2013-05-14 2017-06-06 The University Of Chicago Modulation of reactivation of a latent virus
US20160136123A1 (en) * 2013-06-14 2016-05-19 Vojo P. Deretic Treatment of autophagy-related disorders
EP3027755B1 (en) 2013-08-02 2019-10-09 The Regents of The University of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
EP3062808B1 (en) * 2013-10-28 2021-09-29 The Regents of the University of California Treatment of metastatic prostate cancer
EP4491180A1 (en) 2014-01-10 2025-01-15 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CN103751854B (zh) 2014-01-20 2015-08-26 瞿介明 抗菌医用导管
MX379450B (es) 2014-10-23 2025-03-11 Singh Biotechnology Llc Anticuerpos de un solo dominio dirigidos contra antígenos intracelulares
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
JP6047203B2 (ja) 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および／または治療のための宿主防御タンパク質（ｈｄｐ）模倣薬
US9566399B1 (en) 2015-04-14 2017-02-14 Clempharma LLC Deep lung alveolar aerosol targeted drug delivery
AU2015393953B2 (en) 2015-05-01 2021-09-02 Board Of Regents, The University Of Texas System Multidrug brittle matrix compositions
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
CN105063018A (zh) * 2015-08-31 2015-11-18 山西大学 一种从葡萄成熟果实中提取总rna的方法
EA201890618A1 (ru) 2015-09-01 2018-10-31 Ферст Вэйв Байо, Инк. Способы и композиции для лечения состояний, ассоциированных с аномальными воспалительными ответами
EP3168211A1 (en) 2015-11-10 2017-05-17 Westfälische Wilhelms-Universität Münster Pharmaceutical co-crystals of niclosamide
US10189797B2 (en) 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use
US10588864B2 (en) 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery
WO2017223491A1 (en) 2016-06-23 2017-12-28 Health Research, Inc. Pharmaceutical compositions with antiflaviviral activity
BR112019000796A2 (pt) 2016-07-16 2019-04-24 Florida State University Research Foundation, Inc. compostos e métodos para tratamento e prevenção da infecção flavivirus
KR101928543B1 (ko) 2017-01-09 2018-12-13 사단법인 분자설계연구소 니클로사마이드를 함유하는 Axin-GSK3 단백질 결합 관련 질환 치료용 약학조성물
WO2018136559A1 (en) 2017-01-17 2018-07-26 The Regents Of The University Of California Methods for treating flaviviruses and zika infections
CN110381960A (zh) 2017-02-02 2019-10-25 麦克马斯特大学 作为抗微生物剂的增强剂的碳酸氢盐
CA3057284A1 (en) 2017-03-21 2018-09-27 Novalead Pharma Inc. Therapeutic agent for phosphodiesterase inhibition and its related disorders
FI3612262T3 (fi) 2017-04-18 2024-01-16 Inspiring Pty Ltd Kuivajauheinhalaattori ja kuivajauheinhalaattorin tilanjatkeväline
WO2018205016A1 (en) 2017-05-08 2018-11-15 The Governors Of The University Of Alberta Peroxisome biomarkers in hiv disease progression and peroxisome activating drugs for hiv treatment
CN110799231B (zh) 2017-05-19 2022-08-02 精呼吸股份有限公司 干粉输送装置及其使用方法
US20200405643A1 (en) 2017-09-11 2020-12-31 Board Of Regents, The University Of Texas System Drug compositions containing porous carriers made by thermal or fusion-based processes
WO2019051437A1 (en) 2017-09-11 2019-03-14 Board Of Regents, The University Of Texas System COMPOSITIONS FOR ENHANCED MEDICATION DELIVERY
AU2018392458B2 (en) 2017-12-21 2025-06-26 Merz Pharmaceuticals, Llc Surfactant formulations for inhalation
US20210161937A1 (en) 2018-01-23 2021-06-03 The Trustees Of Columbia University In The City Of New York Activation of mitochondrial uncoupling as a therapeutic intervention
WO2019217164A1 (en) 2018-05-09 2019-11-14 Reyoung Corporation Compositions and methods for treating cancer and other diseases
US11166926B2 (en) 2018-08-08 2021-11-09 The Hospital For Sick Children Compositions and methods for protecting a host from enteric toxigenic pathogens
BR112022003434A2 (pt) 2019-08-23 2022-05-24 Dae Woong Pharma Composição de liberação retardada de niclosamida e uso antiviral da mesma
US20210114973A1 (en) 2019-10-18 2021-04-22 First Wave Bio, Inc. Pharmaceutical formulations
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
US11045434B1 (en) 2020-04-01 2021-06-29 UNION therapeutics A/S Niclosamide formulations for treating disease

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11452692B2 (en) 2018-09-28 2022-09-27 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
US11471413B2 (en) 2018-09-28 2022-10-18 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
US11890378B2 (en) 2018-09-28 2024-02-06 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarinic receptor activation

Also Published As

Publication number Publication date
US11793777B2 (en) 2023-10-24
CA2997136A1 (en) 2017-03-09
US20240074995A1 (en) 2024-03-07
US10744103B2 (en) 2020-08-18
US10772854B2 (en) 2020-09-15
US10292951B2 (en) 2019-05-21
BR112018004069A2 (pt) 2021-07-13
AU2023203354A1 (en) 2023-07-06
CN109562137A (zh) 2019-04-02
US20200276140A1 (en) 2020-09-03
US10905666B2 (en) 2021-02-02
US10849867B2 (en) 2020-12-01
JP6955648B2 (ja) 2021-10-27
US20200147013A1 (en) 2020-05-14
IL257801A (en) 2018-04-30
MX2018002586A (es) 2020-11-24
KR20180080189A (ko) 2018-07-11
US10799468B2 (en) 2020-10-13
MX2022014310A (es) 2022-12-07
PH12018500448A1 (en) 2018-09-24
JP7189983B2 (ja) 2022-12-14
MX2023014409A (es) 2023-12-13
TN2018000069A1 (en) 2019-07-08
WO2017040864A1 (en) 2017-03-09
CR20180185A (es) 2018-12-06
EA201890618A1 (ru) 2018-10-31
SG10201914118SA (en) 2020-02-27
AU2016315852B2 (en) 2023-06-15
EP3344274A4 (en) 2019-05-22
UA125747C2 (uk) 2022-06-01
US20190298670A1 (en) 2019-10-03
US20200197340A1 (en) 2020-06-25
EP3344274A1 (en) 2018-07-11
JP2021098727A (ja) 2021-07-01
US20170056347A1 (en) 2017-03-02
AU2016315852A1 (en) 2018-03-22
PE20181295A1 (es) 2018-08-07
CO2018003465A2 (es) 2018-08-31
JP2018529762A (ja) 2018-10-11
US20200197339A1 (en) 2020-06-25
US10912746B2 (en) 2021-02-09
US20220000812A1 (en) 2022-01-06
US20200268694A1 (en) 2020-08-27
US20200147012A1 (en) 2020-05-14
HK1258048A1 (zh) 2019-11-01
US20210401784A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
CL2021000622A1 (es) Uso de niclosamida para la preparación de un medicamento para el tratamiento de colitis autoinmune, una enfermedad inflamatoria intestinal, colitis autoinmune iatrogénica, divisional de la solicitud de patente nº 559-2018.
das Neves et al. Polymer-based nanocarriers for vaginal drug delivery
ES2509892T3 (es) Administración de un agente para limpieza del intestino y antibiótico para el tratamiento de enfermedad intestinal
CL2020001579A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino. (divisional solicitud 201303145)
CO6531427A2 (es) Composiciones de corticosteriodes administradas oralmente
UY37370A (es) Métodos para tratar esofagitis eosinofílica
MX392606B (es) Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina.
CL2013000063A1 (es) Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion.
MX363000B (es) Composiciones y usos de las mismas para tratar la inflamación.
CL2011000099A1 (es) Uso de una beta-defensina humana en la manufactura de un medicamento que sirve para el tratamiento de una enfermedad intestinal inflamatoria.
BR112012016543A2 (pt) Tratamento com vb-201
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
ECSP21031200A (es) Uso de reboxetina para el tratamiento de narcolepsia
MX2021002633A (es) Dispersiones solidas de bendamustina e infusion continua.
CL2016000170A1 (es) Combinación de oxicodona y naloxona para su uso en el tratamiento del dolor en pacientes que sufren de dolor y una enfermedad que resulta en disbiosis intestinal y/o aumento del riesgo de la translocación bacteriana intestinal.
RU2015122833A (ru) Способ лечения хронического эндометрита
MX2015009681A (es) Un medicamento combinado que comprende finilefrina y paracetamol.
PE20171340A1 (es) Composicion farmaceutica para el tratamiento de enfermedades gastrointestinales
BR112018011483A2 (pt) métodos e composições farmacêuticas com estradiol vaginalmente inserido
MX372644B (es) Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro.
CO2018010142A2 (es) Proceso de preparación de fórmulas solidas de mesalazina
CL2017003465A1 (es) Uso combinado de bumetanida con ácido valproico o una de sus sales farmacéuticamente aceptables para restablecer la homeostasis de cl- y con ello, permitir la preparación de un fármaco efectivo en el tratamiento de la epilepsia, y especialmente, en el tratamiento de la epilepsia refractaria.
HK1253274A1 (zh) 用於治疗炎症性肠病的类囊体提取物组合物和配制剂
Kuiper Perforating folliculitis: case report
Chen et al. Reversing metabolic diseases through diabetes surgery: do the proximal gut and related hormones play key roles in glucose homeostasis?